SCHEMBL25529231

SCHEMBL25529231

COC(=O)c1c2n(ccc1=O)CCOC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 1/20 0.40
MGLL Q99685 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867907 0.81 KDM4E (0.30) ALDH1A1HTTKDM4E
SCHEMBL25529232 0.76 SMN1; SMN2 (0.44) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL25529240 0.74 ALDH1A1 (0.39) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL25529243 0.71 ALDH1A1 (0.39) ALDH1A1HPGDALOX15HSD17B10KMT2A
SCHEMBL15157642 0.69 ALDH1A1 (0.45) ALDH1A1HSD17B10SMN1; SMN2RAB9ALMNA
SCHEMBL27218069 0.69 CNR2 (0.33) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL26967948 0.69 PDE3B (0.32) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL30791523 0.67 KDM4E (0.38) ALDH1A1ALOX15HSD17B10KMT2AMEN1
SCHEMBL15166031 0.67 ABCB1 (0.38) ALDH1A1KMT2ASMN1; SMN2POLBMAPT
SCHEMBL25818344 0.66 KCNK3 (0.34) ALDH1A1HPGDHSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117440951-A Pyridone compounds and methods of use 埃克塞里艾克西斯公司 2024-01-23 CN disclosed
EP-4294804-A1 PYRIDONE COMPOUNDS AND METHODS OF USE Exelixis, Inc. (US) 2023-12-27 EP disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
WO-2022178205-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. (US) 2022-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX ALDH1A1 3998/4885HPGD 1359/4885ALOX15 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.